KALA BIO, Inc. (KALA)

Market Cap	73.71M +246.1%
Revenue (ttm)	n/a
Net Income	-26.98M
EPS	-165.56
Shares Out	18.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,525
Open	4.130
Previous Close	0.083
Day's Range	3.300 - 4.180
52-Week Range	0.066 - 20.600
Beta	-2.24
Analysts	Buy
Price Target	31.50 (+694.45%)
Earnings Date	May 19, 2026

About KALA

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA
• Website: https://www.kalarx.com

Analyst Summary

According to 3 analysts, the average rating for KALA stock is "Buy." The 12-month stock price target is $31.5, which is an increase of 694.45% from the latest price.

Price Target

$31.5

(694.45% upside)

Analyst Consensus: Buy